ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $89.15M | $30.00K | $1.32M | $5.51M | $17.84M | N/A | N/A |
| Cost of Revenue | $20.56M | N/A | N/A | $213.00K | $14.07M | $1.55M | $1.42M |
| Gross Profit | $68.59M | $30.00K | $1.32M | $5.29M | $3.77M | $-1.55M | $-1.42M |
| Gross Margin | 76.94% | 100.00% | 100.00% | 96.13% | 21.11% | 0.00% | 0.00% |
| Operating Expenses | $71.67M | $67.55M | $36.83M | $24.75M | $4.23M | $22.52M | $16.90M |
| Operating Income | $-3.08M | $-67.52M | $-35.52M | $-19.45M | $-469.00K | $-24.07M | $-18.32M |
| Operating Margin | -3.46% | -225066.67% | -2698.78% | -353.32% | -2.63% | 0.00% | 0.00% |
| Net Income | $8.00M | $-54.37M | $-34.68M | $-20.24M | $-1.06M | $-23.97M | $-17.58M |
| Net Margin | 8.97% | -181216.67% | -2635.41% | -367.65% | -5.97% | 0.00% | 0.00% |
| EPS (Basic) | $0.08 | $-0.57 | $-0.87 | $-0.70 | $-0.03 | $-0.72 | $-0.53 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |